Kenneth Avocetien
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kenneth Avocetien has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alex Uttard
Mersana Therapeutics, Cambridge, Massachusetts
19 shared publications - Bingfan Du
Mersana Therapeutics, Cambridge, Massachusetts
19 shared publications - David H. Lee
Mersana Therapeutics, Cambridge, Massachusetts
19 shared publications - Dokyong Kim
Mersana Therapeutics, Cambridge, Massachusetts
19 shared publications - Dorin Toader
Mersana Therapeutics, Inc., Cambridge, Massachusetts
19 shared publications - Elizabeth Ditty
Mersana Therapeutics, Inc., Cambridge, Massachusetts
19 shared publications
Latest Publications
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Data File 1 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Complete synthetic route for Monomeric Dolasynthen linker-scaffold-payload
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Data File 1 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Complete synthetic route for Monomeric Dolasynthen linker-scaffold-payload
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S3 shows body weights of animals at two doses
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S3 shows body weights of animals at two doses
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Table S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S4 compares the nominal DAR to the calculated DAR values from measured Cmax values for each ADC
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S4 compares the nominal DAR to the calculated DAR values from measured Cmax values for each ADC
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S2 shows a graphical representation of IC50 spread over range of cytotoxicity experiments
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S2 shows a graphical representation of IC50 spread over range of cytotoxicity experiments
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S4 compares the body weights of mice dosed with DAR2 and DAR18 ADCs at matched payload and antibody doses
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S4 compares the body weights of mice dosed with DAR2 and DAR18 ADCs at matched payload and antibody doses
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S3 contains response numbers for in vivo efficacy study
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S3 contains response numbers for in vivo efficacy study
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S3 contains response numbers for in vivo efficacy study
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S3 contains response numbers for in vivo efficacy study
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S4 compares the body weights of mice dosed with DAR2 and DAR18 ADCs at matched payload and antibody doses
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S4 compares the body weights of mice dosed with DAR2 and DAR18 ADCs at matched payload and antibody doses
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S2 supplies IC50 values for ADCs over a range of in vitro cytotox assays
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S2 supplies IC50 values for ADCs over a range of in vitro cytotox assays
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S2 shows a graphical representation of IC50 spread over range of cytotoxicity experiments
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S2 shows a graphical representation of IC50 spread over range of cytotoxicity experiments